IDEAYA Biosciences heads into the week after reporting earnings with the Street still constructive but quietly trimming targets, while short sellers who spent June building positions have spent July unwinding them.
The most striking shift in IDYA's positioning is the magnitude of short covering that has occurred over the past five weeks. Short interest peaked above 11.2 million shares in late June and has since fallen to roughly 9.5 million — a decline of about 15% — bringing the short position to 10.8% of the free float. That is still a meaningful level for a clinical-stage biotech, but the direction of travel is clearly one of retreat rather than accumulation. Borrow conditions reinforce that picture: the cost to borrow has eased to around 0.42%, down from above 0.57% in late June, and availability is exceptionally loose at roughly 926% — meaning there are nearly ten shares available to borrow for every one currently shorted. The borrow market carries no squeeze pressure whatsoever.
Options positioning adds another layer of calm to the setup. The put/call ratio has dropped to 0.38, sitting below its 20-day average of 0.45, and the reading is near the lower end of the past year's range — the 52-week PCR low is just 0.006, while the high reached 2.34 during a period of acute hedging anxiety. The current lean toward calls suggests investors coming out of the earnings event are more interested in upside participation than in protecting against downside. That flip is notable given how heavily put-weighted the options book was through June and into mid-July, when the PCR was running consistently above 0.65.
The Street's view on IDYA remains broadly positive, though analysts are selectively adjusting their numbers post-earnings. Today, Truist Securities maintained its Buy rating but trimmed its target from $63 to $59, while Wedbush nudged its Outperform target slightly higher to $60 from $58. The consensus mean target is $53, implying roughly 47% upside from the current $36.11 close — a gap that reflects the binary nature of the pipeline rather than near-term fundamental confidence. Goldman Sachs remains the notable outlier with a Neutral rating and a $35 target, practically in line with the current price; the divergence between Goldman's cautious stance and the bullish majority captures the stock's split personality well. Bulls point to the consistent clinical efficacy of the darovasertib program and the GlaxoSmithKline collaboration providing funding runway. Bears flag the absence of pivotal overall survival data and the historical pattern of Grade 3+ adverse events in the trial data. EPS surprise factor sits at the 75th percentile, a genuine positive, though forward EPS momentum ranks in the bottom quartile of the universe — a reminder that this is still a company burning cash with no near-term earnings inflection.
Institutional ownership tells a stable story. FMR holds 13.9% of shares and added modestly through the June quarter. BlackRock and State Street both grew positions in the same period. The one notable move on the insider ledger over the past 90 days was a $382,000 sale by the Principal Accounting Officer in early July at $40 — a routine disposal, not a signal, and modest relative to the $1.65 million open-market purchase made by Independent Director Jeffrey Stein in March at $32.96, which still stands as the most recent buy on record.
The two most recent earnings events with price-reaction data provide useful context for what just happened. A June 2026 data event produced a 3.4% gain on the day and a 15.5% rally over the subsequent five days. The May 2026 print landed flat to slightly lower on the day but was essentially unchanged over the following week. With the next scheduled event now pushed out to November 5, the stock's path from here will be driven by any interim clinical data disclosures, pipeline updates from the GSK collaboration, and whether the short covering that dominated July resumes or stalls near current levels.
See the live data behind this article on ORTEX.
Open IDYA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
